Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.

Literature DB >> 12543692

Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.

Anne J M Lenaerts¹, Veronica Gruppo, Jason V Brooks, Ian M Orme.

Abstract

We have developed a rapid new in vivo method for screening experimental drugs for their activity against Mycobacterium tuberculosis by using the gamma interferon gene-disrupted (GKO) C57BL/6 mouse. Due to the rapid growth of the infection, statistical differences indicating positive efficacy of active compounds can be seen after only 8 days of treatment. To validate this model, several fluoroquinolones, including ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin, were tested in parallel.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2003 PMID： 12543692 PMCID： PMC151769 DOI： 10.1128/AAC.47.2.783-785.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

19 in total

1. Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage.

Authors: G CANETTI; F GRUMBACH; J GROSSET
Journal: Tubercle Date: 1963-06

2. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis.

Authors: J M Dickinson; G A Ellard; D A Mitchison
Journal: Tubercle Date: 1968-12

3. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis.

Authors: J M Dickinson; D A Mitchison
Journal: Tubercle Date: 1970-03

4. [Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV].

Authors: F Grumbach; N Rist
Journal: Rev Tuberc Pneumol (Paris) Date: 1967 Sep-Oct

5. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

Authors: J Grosset
Journal: Bull Int Union Tuberc Date: 1978-03

6. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

Authors: H Stass; D Kubitza
Journal: J Antimicrob Chemother Date: 1999-05 Impact factor: 5.790

7. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.

Authors: H M Siefert; A Domdey-Bette; K Henninger; F Hucke; C Kohlsdorfer; H H Stass
Journal: J Antimicrob Chemother Date: 1999-05 Impact factor: 5.790

8. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors: D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal: Science Date: 1993-03-19 Impact factor: 47.728

9. Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors: A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal: J Exp Med Date: 1993-12-01 Impact factor: 14.307

10. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors: J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal: J Exp Med Date: 1993-12-01 Impact factor: 14.307

53 in total

1. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors: Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal: Antimicrob Agents Chemother Date: 2011-12-05 Impact factor: 5.191

Review 2. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors: E Nuermberger; J Grosset
Journal: Eur J Clin Microbiol Infect Dis Date: 2004-03-13 Impact factor: 3.267

3. Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions.

Authors: Jiuyu Liu; David F Bruhn; Robin B Lee; Zhong Zheng; Tanja Janusic; Dimitri Scherbakov; Michael S Scherman; Helena I Boshoff; Sourav Das; Samanthi L Waidyarachchi; Tiffany A Brewer; Begoña Gracia; Lei Yang; John Bollinger; Gregory T Robertson; Bernd Meibohm; Anne J Lenaerts; Jose Ainsa; Erik C Böttger; Richard E Lee
Journal: ACS Infect Dis Date: 2016-11-11 Impact factor: 5.084

4. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors: Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal: Am J Respir Crit Care Med Date: 2005-09-08 Impact factor: 21.405

5. Testing of experimental compounds in a relapse model of tuberculosis using granulocyte-macrophage colony-stimulating factor gene-disrupted mice.

Authors: Lisa K Woolhiser; Donald R Hoff; Karen S Marietta; Ian M Orme; Anne J Lenaerts
Journal: Antimicrob Agents Chemother Date: 2008-10-13 Impact factor: 5.191

6. Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents.

Authors: Rajendra P Tangallapally; Raghunandan Yendapally; Robin E Lee; Anne J M Lenaerts; Richard E Lee
Journal: J Med Chem Date: 2005-12-29 Impact factor: 7.446

7. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Authors: Subramaniam Ananthan; Ellen R Faaleolea; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Barbara E Laughon; Joseph A Maddry; Alka Mehta; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Nice Shindo; Dustin N Showe; Melinda I Sosa; William J Suling; E Lucile White
Journal: Tuberculosis (Edinb) Date: 2009-09-15 Impact factor: 3.131